Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Kantoff, M.D.

Co-Author

This page shows the publications co-authored by Philip Kantoff and Glenn Bubley.
Connection Strength

1.250
  1. Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial. J Clin Oncol. 2021 Sep 10; 39(26):2938-2947.
    View in: PubMed
    Score: 0.243
  2. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20; 32(33):3705-15.
    View in: PubMed
    Score: 0.153
  3. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12.
    View in: PubMed
    Score: 0.126
  4. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006 Jun 20; 24(18):2723-8.
    View in: PubMed
    Score: 0.086
  5. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology. 2004 Feb; 63(2):327-32.
    View in: PubMed
    Score: 0.073
  6. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018 09; 21(3):364-372.
    View in: PubMed
    Score: 0.048
  7. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176.
    View in: PubMed
    Score: 0.044
  8. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):935-945.
    View in: PubMed
    Score: 0.044
  9. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 2015 Aug 01; 121(15):2603-11.
    View in: PubMed
    Score: 0.040
  10. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80.
    View in: PubMed
    Score: 0.038
  11. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
    View in: PubMed
    Score: 0.037
  12. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013 Mar; 81(3):611-6.
    View in: PubMed
    Score: 0.034
  13. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec; 110(11):1729-35.
    View in: PubMed
    Score: 0.033
  14. Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4657.
    View in: PubMed
    Score: 0.030
  15. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105.
    View in: PubMed
    Score: 0.027
  16. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5068.
    View in: PubMed
    Score: 0.024
  17. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9.
    View in: PubMed
    Score: 0.024
  18. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 01; 26(7):1148-59.
    View in: PubMed
    Score: 0.024
  19. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50.
    View in: PubMed
    Score: 0.023
  20. Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4560.
    View in: PubMed
    Score: 0.021
  21. Mifepristone (RU-486) in androgen independent prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14508.
    View in: PubMed
    Score: 0.021
  22. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12.
    View in: PubMed
    Score: 0.019
  23. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000 Dec 06; 92(23):1918-25.
    View in: PubMed
    Score: 0.015
  24. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000 May; 6(5):1632-8.
    View in: PubMed
    Score: 0.014
  25. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol. 1994 Dec; 12(12):2634-9.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.